Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 20;17(1):13.
doi: 10.3390/neurolint17010013.

Optical Coherence Tomography in Huntington's Disease-A Potential Future Biomarker for Neurodegeneration?

Clancy Cerejo  1 , Nicolas De Cleene  1 , Elias Mandler  1 , Katarina Schwarzová  1 , Samuel Labrecque  1 , Philipp Mahlknecht  1 , Florian Krismer  1 , Atbin Djamshidian  1 , Klaus Seppi  1   2 , Beatrice Heim  1
Affiliations
Review

Optical Coherence Tomography in Huntington's Disease-A Potential Future Biomarker for Neurodegeneration?

Clancy Cerejo et al. Neurol Int. .

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder for which, until now, only symptomatic treatment has been available. Lately, there have been multiple ongoing clinical trials targeting therapeutic agents for preventing disease onset or slowing disease progression in HD. These studies are in constant need of reliable biomarkers for neurodegeneration in HD. In recent years, retinal biomarkers have attracted significant attention in neurodegenerative disorders. Likewise, optical coherence tomography (OCT) is being evaluated as a potential biomarker in HD. In this article, we review the existing literature on OCT as a biomarker for neurodegeneration in HD.

Keywords: Huntington's disease; neurodegeneration; optical coherence tomography.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to report.

Figures

Figure 1
Figure 1
Heidelberg Spectralis optical coherence tomography of normal retinal nerve fibre layer (RNFL) thickness.
See this image and copyright information in PMC

References

    1. Ghosh R., Tabrizi S.J. Clinical features of Huntington's disease. Adv. Exp. Med. Biol. 2018;1049:1–28. - PubMed
    1. McColgan P., Tabrizi S.J. Huntington's disease: A clinical review. Eur. J. Neurol. 2018;25:24–34. doi: 10.1111/ene.13413. - DOI - PubMed
    1. Bates G.P., Dorsey R., Gusella J.F., Hayden M.R., Kay C., Leavitt B.R., Nance M., Ross C.A., Scahill R.I., Wetzel R., et al. Huntington disease. Nat. Rev. Dis. Primers. 2015;1:15005. doi: 10.1038/nrdp.2015.5. - DOI - PubMed
    1. Hogarth P., Kayson E., Kieburtz K., Marder K., Oakes D., Rosas D., Shoulson I., Wexler N.S., Young A.B., Zhao H., et al. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov. Disord. 2005;20:293–297. doi: 10.1002/mds.20332. - DOI - PubMed
    1. Liu D., Long J.D., Zhang Y., Raymond L.A., Marder K., Rosser A., McCusker E.A., Mills J.A., Paulsen J.S., PREDICT-HD Investigators and Coordinators of the Huntington Study Group Motor onset and diagnosis in Huntington disease using the diagnostic confidence level. J. Neurol. 2015;262:2691–2698. doi: 10.1007/s00415-015-7900-7. - DOI - PMC - PubMed

LinkOut - more resources